5AM Ventures
191
39M
92
8.68
40
0.51
40
- Stages of investment
- Areas of investment
Summary
5AM Ventures appeared to be the VC, which was created in 2002. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Menlo Park.
The fund has no exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline Audentes Therapeutics, Ikaria, Relypsa We can highlight the next thriving fund investment areas, such as Life Science, Therapeutics.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the 5AM Ventures, startups are often financed by Clarus Ventures, ARCH Venture Partners, Sprout Group. The meaningful sponsors for the fund in investment in the same round are Roche Venture Fund, Frazier Healthcare Partners, Clarus Ventures. In the next rounds fund is usually obtained by ARCH Venture Partners, Roche Venture Fund, Aravis Ventures.
The current fund was established by Andrew Schwab, John Diekman. Besides them, we counted 8 critical employees of this fund in our database.
The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 12 percentage points more often commits exit comparing to other companies. When the investment is from 5AM Ventures the average startup value is 10-50 millions dollars. Opposing the other organizations, this 5AM Ventures works on 8 percentage points less the average amount of lead investments. The top amount of exits for fund were in 2018. The fund is constantly included in 7-12 deals per year.
Investments analytics
Analytics
- Total investments
- 191
- Lead investments
- 40
- Exits
- 40
- Rounds per year
- 8.68
- Follow on index
- 0.51
- Investments by industry
- Biotechnology (171)
- Health Care (104)
- Therapeutics (86)
- Pharmaceutical (48)
- Medical (43) Show 32 more
- Investments by region
-
- United States (174)
- Switzerland (7)
- United Kingdom (3)
- Sweden (2)
- Singapore (1) Show 1 more
- Peak activity year
- 2018
- Number of Unicorns
- 5
- Number of Decacorns
- 5
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Avg. valuation at time of investment
- 118M
- Group Appearance index
- 0.95
- Avg. company exit year
- 6
- Avg. multiplicator
- 2.69
- Strategy success index
- 0.90
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Karius | 02 May 2024 | Biotechnology, Information Technology, Genetics, Life Science | Late Stage Venture | 100M | United States, California, Redwood City |
Nido Biosciences | 08 Sep 2020 | Biotechnology, Health Care, Personal Health | Early Stage Venture | 18M | United States, Massachusetts, Boston |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.